abatacept.tw. 7. for use in any indication (with the exception of HIV/AIDS) and that reported our pre\specified adverse outcomes (serious adverse events (SAEs), withdrawals due to adverse events (AEs), total AEs, serious infections; specific AEs, namely, tuberculosis (TB) reactivation, lymphoma and congestive heart failure) were considered for inclusion. We searched mean(SD; median)9.8 (11.5; 6.0)20.7 (17.9; 13.5)Trial duration, short 6 months , N studies989Trial duration: intermediate (6 mo. 12), N studies2712Trial duration: long 12 months , N studies3525mean(SD; median)49.9 (8.2; 51)79.9 (24.2; 87.0)mean(SD; median)58.9 (20.4; 61)57.3 (24.5; 61.7)mean(SD; median)85.4(17; 89.7)79.9 (24.2; 87.0) Open in a separate window IBD = inflammatory bowel disease; SD = standard deviation; *other conditions for RCT include: heart failure, multiple sclerosis, COPD, alcoholic hepatitis, diabetes, lupus, active spondylarthropathy, osteoarthritis, asthma, cardiac or renal transplantation, Sjogren’s syndrome, polymyalgia rheumatica, autoimmune inner ear disease, giant cell arteritis, pulmonary sarcoidosis, Hepatitis C, cancer anorexia/weight loss syndrome, Wegener’s granulomatosis; other conditions for OLE = sarcoidosis, axial spondylarthritis; *** one study (Schiff 2008) had two treatment arms (abatacept and infliximab) Concordance of assessment of included studies There were 10 review groups each providing two review authors.?The articles were randomly distributed to the review groups and the articles within a review group were assessed independently by each of the two review authors and consensus was obtained.?To evaluate agreement across the 10 review groups, two articles were assessed by each of the groups who were unaware that these two articles were being assessed across the A-443654 groups for quality assurance purposes.?The results of this assessment indicated a high degree of agreement with the safety data being extracted, with concordance; the kappa exceeded 0.9 and the only area of discrepancy concerned the assessment of the risk of bias. Methodological quality of included reviews We presented summaries of the methodological quality of the included studies for each of the domains we assessed. Results are presented separately for RCTs and OLEs. Details on the judgement for each included study and the reason for that judgement are available at the following website: Cochrane Musculoskeletal Group Rabbit Polyclonal to CYC1 website. Randomized controlled trials Allocation sequence: 45 of 160 RCTs (28.1%) reported adequate methods for allocation sequence and were judged to be at low risk of bias. One hundred and twelve RCTs (70 %70 %) did not provide enough information to assess allocation sequence and the risk of bias was judged to be unclear for these studies. Three of the RCTs (1.9%), reported inadequate methods for allocation concealment including biased coin assignment (Menter 2007), simple block randomization (Pavelka 2009), and sequential allocation (Cassano 2006). These three studies were judged to be at high risk of bias for allocation sequence. Allocation concealment: 60 of 160 RCTs (37.5%) reported adequate methods for allocation concealment and were judged to be at low risk of bias. Ninety\six A-443654 RCTs (60%), did not provide enough information to assess allocation concealment and the risk of bias was judged to be unclear for these studies. Four studies (2.5%) were judged to be at high risk of bias for allocation concealment. Three of these RCTs were open\label studies ( Buske 2009; Eve 2009; Hiddemann A-443654 2005) and one study used sequential allocation to assign patients to treatment (Cassano 2006). Blinding of personnel: 65 of 160 RCTs (40.6%) reported adequate methods for blinding personnel to treatment allocation. Seventy\eight RCTs (48.8%) did not provide enough information to assess the blinding of personnel and the risk of bias was judged to be unclear for these studies. Seventeen studies (10.6%) were judged to be at high risk of bias for blinding of personnel. Nine of these RCTs were open\label studies (Buske 2009; Coiffier 1998; Eve 2009; Forstpointner 2002; Forstpointner 2004; Herold 2007; Hiddemann 2005; Ortonne 2008; Salles 2007;), no blinding was reported in one study (Hainsworth 2005), unmasking or unblinding was reported in four studies (Genovese 2002a; Kavanaugh 2000; Pavelka 2009; Pfreundschuh 2006). Patients and doctors were aware of treatment A-443654 allocation in the Van Vollenhoven 2009 study. In the Schrieber 2005 study the treatment and placebo looked different. In the Van der Bijl 2009 study, injections were given by a non\blinded independent investigator. Blinding of participants: 75 of 160 RCTs (46.9%) reported adequate methods for blinding participants to treatment allocation. Sixty\nine RCTs (43.1%) did not provide enough information to assess the blinding of participants and the risk of bias was judged to be unclear for these studies. Sixteen studies (10%).